The Discovery of Sotorasib (AMG 510): First-in-Class Investigational Covalent Inhibitor of KRAS G12C. ... How covalent inhibition helped to turn KRAS G12C into a tractable target ; What hurdles were ...

This led to the belief that covalent inhibitors were not ideal drug candidates resulting in limited development by the pharmaceutical industry. However, covalent drugs have experienced a remarkable ...

For patients with non–small cell lung cancer, sotorasib should not be used within 30 days of immune check point inhibitors (ICIs) because of increased toxicity, say French researchers.

VIENNA -- Using sotorasib (Lumakras) as "lead-in" therapy prior to combining it with immunotherapy was feasible as first-line therapy for patients with advanced KRAS G12C non-small cell lung ...

Using sotorasib as a lead-in therapy with pembrolizumab or atezolizumab for patients with advanced KRAS p.G12C non-small cell lung cancer demonstrated durable clinical activity with lower rates of ...

More information: Ferdinandos Skoulidis et al, Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer, Nature Medicine (2025). DOI: 10.1038/s41591-025 ...

Sotorasib exhibited durable efficacy among certain adults with locally advanced or metastatic non-small cell lung cancer, according to study results presented at American Association for Cancer ...

Sotorasib prolonged PFS compared with standard chemotherapy for certain patients with non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

Sotorasib selectively and irreversibly inhibits the KRAS G12C protein to block downstream proliferation and survival signaling. 10 Although single-agent KRAS G12C inhibitors (sotorasib and ...

Sotorasib is "a triumph of drug discovery," commented Colin Lindsay, MD, from the University of Manchester, UK, the invited discussant. "We know that KRAS, over many years, over three decades, has ...

Sotorasib is a small-molecule inhibitor that irreversibly binds the mutant KRAS G12C protein to lock it in an inactive state. In 2021, this targeted therapy was approved by the Food and Drug ...

1.1 Sotorasib is recommended for use within the Cancer Drugs Fund as an option for treating KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose ...